Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| T-817 SCHEMBL27725 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| T-817 SCHEMBL47926 | 0.99 | SIGMAR1 (0.98) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| SCHEMBL27025 | 0.95 | SIGMAR1 (0.91) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| Hydrochloric Acid SCHEMBL47954 | 0.94 | SIGMAR1 (0.89) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| SCHEMBL47923 | 0.93 | SIGMAR1 (0.87) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| T-817 SCHEMBL4134384 | 0.93 | SIGMAR1 (0.86) | SIGMAR1CYP2A6OPRM1OPRK1HCRTR1 | |
| T-817 SCHEMBL48195 | 0.93 | SIGMAR1 (0.86) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| SCHEMBL48249 | 0.92 | SIGMAR1 (0.85) | SIGMAR1CYP2A6OPRM1OPRK1HRH3 | |
| Hydrochloric Acid SCHEMBL47938 | 0.92 | SIGMAR1 (0.85) | SIGMAR1CYP2A6OPRM1OPRK1SLC6A4 | |
| T-817 SCHEMBL48064 | 0.92 | SIGMAR1 (1.00) | SIGMAR1CYP2A6OPRM1OPRK1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024220459-A2 | COMBINATION THERAPY WITH LP-PLA2 INHIBITOR AND A SECOND AGENT | SCINEURO THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-4680633-A1 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS | Alzpath, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260008840-A1 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS | ALZPATH INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250223645-A1 | NEURONAL METHYLATION SIGNATURES FROM CELL FREE DNA AS A PRE-SYMPTOMATIC NEURODEGENERATIVE CONDITION SURVEILLANCE DIAGNOSTIC | RESONANT LLC (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025030152-A2 | NEURONAL METHYLATION SIGNATURES FROM CELL FREE DNA AND METHODS OF USE THEREOF | RESONANT LLC (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250043351-A1 | NEURONAL METHYLATION SIGNATURES FROM CELL FREE DNA AND METHODS OF USE THEREOF | RESONANT LLC | 2025-02-06 | — | — | US | disclosed |
| EP-4497139-A2 | NEURONAL METHYLATION SIGNATURES FROM CELL FREE DNA AS A PRE-SYMPTOMATIC NEURODEGENERATIVE CONDITION SURVEILLANCE DIAGNOSTIC | Resonant LLC (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2024238387-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-11-21 | — | — | WO | disclosed |
| CN-118974835-A | Neuronal methylation markers from cell-free DNA as monitoring diagnostics for pre-symptomatic neurodegenerative disorders | 莱索南特有限责任公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024220459-A2 | COMBINATION THERAPY WITH LP-PLA2 INHIBITOR AND A SECOND AGENT | SCINEURO THERAPEUTICS INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024192404-A1 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS | ALZPATH, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024178386-A1 | METHODS OF TREATING ENDOSOMAL TRAFFICKING DISEASES | AARHUS UNIVERSITET (DK) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024036005-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023178109-A2 | NEURONAL METHYLATION SIGNATURES FROM CELL FREE DNA AS A PRE-SYMPTOMATIC NEURODEGENERATIVE CONDITION SURVEILLANCE DIAGNOSTIC | RESONANT LLC (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | SIGMAR1 4828/4885CYP2A6 3814/4885OPRM1 4611/4885 |
| US-20260008840-A1 | METHODS OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISORDERS | MAPT, NEFM, APP | SIGMAR1 4414/4885CYP2A6 4813/4885OPRM1 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.